Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: Study of a series of 100 patients

Medicine

Volumn 86, Issue 4, 2007, Pages 233-241

  Hernández Rodríguez, José ^a   Font, Carme ^a   García Martínez, Ana ^a   Espígol Frigolé, Georgina ^a   Sanmartí, Raimon ^a   Cañete, Juan D ^a   Grau, Josep M ^a   Cid, Maria C ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CHRONOLOGY; CLINICAL FEATURE; CONTROLLED STUDY; COURSE EVALUATION; DIPLOPIA; DISEASE COURSE; FEMALE; GIANT CELL ARTERITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL EXAMINATION; PATIENT SELECTION; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; RISK ASSESSMENT; SAMPLE SIZE; STROKE; SYMPTOM; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; BLINDNESS; CEREBROVASCULAR ACCIDENT; FEMALE; GLUCOCORTICOIDS; HEADACHE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; POLYMYALGIA RHEUMATICA; PREDNISONE; TEMPORAL ARTERITIS;

EID: 34447537657     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e318145275c     Document Type: Article

References (56)

1. Alestig K, Barr J. Giant-cell arteritis. A biopsy study of polymyalgia rheumatica, including one case of Takayasu's disease. Lancet. 1963;1:1228-1230.
2. Armona J, Rodriguez-Valverde V, Gonzalez-Gay MA, Figueroa M, Fernandez-Sueiro JL, Blanco R, Martinez-Taboada V. Giant cell arteritis. A study of 191 patients. Med Clin (Barc). 1995;105:734-737.
3. Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985;79:309-315.
4. Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol. 1998;25:99-104.
5. Barber HS. Myalgic syndrome with constitutional effects; polymyalgia rheumatica. Ann Rheum Dis. 1957;16:230-237.
6. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis. 1983;42:374-378.
7. Bella Cueto F, Costa Roma J, Gonzalez de Zarate P, Pujol Farriol R, Aguirre Errasti L, Martinez LdLJ. Giant cell arteritis. Multicenter study of 100 cases with positive biopsies. Med Clin (Barc). 1985;85:43-48.
8. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications. Arthritis Rheum. 1981;24:899-904.
9. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007;46:672-677.
10. Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, Boiardi L, Salvarani C. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum. 2004;33:294-301.
11. Chakravarty K, Pountain G, Merry P, Byron M, Hazleman B, Scott DG. A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis. J Rheumatol. 1995;22:1694-1697.
12. Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97:672-680.
13. Cid MC, Ercilla G, Vilaseca J, Sanmarti R, Villalta J, Ingelmo M, Urbano-Marquez A. Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. Arthritis Rheum. 1988;31:678-682.
14. Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, Lopez-Soto A, Vilaseca J, Urbano-Marquez A, Grau JM. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998;41:26-32.
15. Cid MC, Hernandez-Rodriguez J, Grau JM. Vascular manifestations in giant-cell arteritis. In: Asherson R, Tripplet D, Cervera R, eds. Vascular Manifestations of Systemic Autoimmune Diseases. Boca Raton, FL: CRC Press; 2001:237-249.
16. Cuddigan JH. Steroid treatment in giant cell arteritis. Br J Rheumatol. 1993;32:434.
17. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29:456-458.
18. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis. 1988;47:733-739.
19. Fauchald P, Rygvold O, Oystese B. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings. Ann Intern Med. 1972;77:845-852.
20. Fessel WJ, Pearson CM. Polymyalgia rheumatica and blindness. N Engl J Med. 1967;276:1403-1405.
21. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289-293.
22. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84:269-276.
23. Gonzalez-Gay MA, Garcia-Porrúa C, Llorca J, Hajeer AH, Branas F, Dababneh A, Gonzalez-Louzao C, Rodriguez-Gil E, Rodriguez-Ledo P, Ollier WE. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283-292.
24. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol. 1998;25:1750-1755.
25. Hamrin B. Polymyalgia arteritica. Acta Med Scand Suppl. 1972;533:1-131.
26. Harrison MJ, Bevan AT. Early symptoms of temporal arteritis. Lancet. 1967;2:638-640.
27. Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol. 1992;19:270-272.
28. Hernandez-Rodriguez J, Font C, Coll-Vinent B, Casademont J, Lopez-Soto A, Grau JM, Cid MC. Cranial ischemic events in giant-cell arteritis patients (GCA) presenting with apparently isolated polymyalgia rheumatica (PMR). Arthritis Rheum. 1998;41(Suppl):S121.
29. Hernandez-Rodriguez J, Garcia-Martinez A, Casademont J, Filella X, Esteban MJ, Lopez-Soto A, Fernandez-Sola J, Urbano-Marquez A, Grau JM, Cid MC. A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. Arthritis Rheum. 2002;47:29-35.
30. Hernandez-Rodriguez J, Garcia-Martinez A, Espigol-Frigole G, Grau JM, Collado A, Cid MC. Sustained spontaneous clinical remission in giant cell arteritis: report of two cases with long-term followup. Arthritis Rheum. 2006;55:160-162.
31. Horton BT, Magath TB, Brown GE. An undescribed form of arteritis of the temporal vessels. Proc Staff Meet Mayo Clin. 1932;7:700-701.
32. Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc. 2006;81:1071-1083.
33. Hunder GG, Valente RM. Giant-cell arteritis: clinical aspects. In: Hoffman GS, Weyand CM, eds. Inflammatory Disease of Blood Vessels. New York: Marcel Dekker; 2002:425-441.
34. Hutchinson J. Diseases of the arteries. Arch Surg (London). 1890;1:323-329.
35. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981;40:1-5.
36. Lie JT, Brown AL Jr, Carter ET. Spectrum of aging changes in temporal arteries. Its significance, in interpretation of biopsy of temporal artery. Arch Pathol. 1970;90:278-285.
37. Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, Vidal E. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med. 2001;111:211-217.
38. Meliconi R, Pulsatelli L, Uguccioni M, Salvarani C, Macchioni P, Melchiorri C, Focherini MC, Frizziero L, Facchini A. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum. 1996;39:1199-1207.
39. Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol. 1996;35:1161-1168.
40. Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol. 1999;26:1945-1952.
41. Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, Sonnenblick M. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore). 2004;83:114-122.
42. Ostberg G. An arteritiswith special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand [A]. 1973;237(Suppl 237): 231-259.
43. Paulley JW. Anarthritic rheumatoid disease. Lancet. 1956;271:946.
44. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286-1294.
45. Rodriguez-Valverde V, Sarabia JM, Gonzalez-Gay MA, Figueroa M, Armona J, Blanco R, Fernandez-Sueiro JL, Martinez-Taboada VM. Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica. Am J Med. 1997;102:331-336.
46. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271.
47. Salvarani C, Cantini F, Olivieri I, Barozzi L, Macchioni L, Niccoli L, Padula A, De Matteis M, Pavlica P. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med. 1997;127:27-31.
48. Salvarani C, Cimino L, Macchioni P, Consonni D, Cantini F, Bajocchi G, Pipitone N, Catanoso MG, Boiardi L. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005;53:293-297.
49. Save-Soderbergh J, Malmvall BE, Andersson R, Bengtsson BA. Giant cell arteritis as a cause of death. Report of nine cases. Jama. 1986;255:493-496.
50. Simkin PA, Healey LA. Giant cell arteritis with polymyalgia rheumatica, loss of vision, and abdominal symptoms occurring during a four year course. Arthritis Rheum. 1969;12:147-151.
51. Sorensen S, Lorenzen I. Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. Acta Med Scand. 1977;201:207-213.
52. Spiera H, Davison S. Long-term follow-up of polymyalgia rheumatica. Mt Sinai J Med. 1978;45:225-229.
53. Spiera H, Davison S. Treatment of polymyalgia rheumatica. Arthritis Rheum. 1982;25:120.
54. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med. 1999;159:577-584.
55. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-491.
56. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum. 1994;37:514-520.